Sign in
Taking peopleNo phase

Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate

Key facts

Who runs it
Jeil Pharmaceutical Co., Ltd.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
3,000 people, planned
Started
2 Nov 2024
Expected to end
31 Dec 2029
Type of study
Observational
Treatments tested
  • zastaprazan citrate
Record updated
26 October 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Patients who receive their first prescription for zastaprazan citrate in accordance with the approved prescribing information after execution of the study agreement
  • Patients who have received an explanation of the study and voluntarily signed the informed consent form

Who cannot take part

  • atients currently receiving products containing atazanavir, nelfinavir, or rilpivirine
  • Patients with hypersensitivity or a history of hypersensitivity to zastaprazan citrate or any component of the product
  • Patients with hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This exclusion criterion does not apply to the orally disintegrating tablet formulation
  • Patients who are pregnant or breastfeeding

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Erosive gastroesophageal reflux disease

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This post-marketing surveillance aims to evaluate the safety and effectiveness of zastaprazan citrate administered in Korean patients receiving the drug in accordance with the approved prescribing information.

The group in the trial

  • Erosive Gastroesophageal Reflux Disease

    Patients administrated zastaprazan citrate

    Treatment: zastaprazan citrate

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07894939, who can take part
Record updated
26 October 2026